<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622178</url>
  </required_header>
  <id_info>
    <org_study_id>11-125E</org_study_id>
    <nct_id>NCT02622178</nct_id>
  </id_info>
  <brief_title>How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?</brief_title>
  <official_title>Sensitivity and Specificity of the NOVA-DN VEP Protocol and a Novel Analysis of Optical Coherence Tomography Images for Glaucoma Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate sensitivity and specificity of NOVA-DN visually evoked potentials (VEP) protocol and
      new software method (Corda) for glaucoma detection using optical coherence tomography (OCT)
      images to differentiate between normal subjects and glaucoma suspects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to evaluate the ability of NOVA-DN VEP protocol and Corda
      parameters to discriminate between healthy eyes and eyes with early to moderate glaucomatous
      visual field loss. We will evaluate measurements of the NOVA-DN VEP protocol, Corda software
      and Cirrus spectral domain (SD) OCT software in order to compare and correlate.

      Hypotheses is that NOVA-DN VEP protocol and Corda analysis results in a high sensitivity,
      specificity and area under the Receiver Operating Characteristic (ROC) curves (ROC area) for
      glaucoma detection. Second hypothesis is NOVA-DN VEP protocol and Corda parameters can
      differentiate between normal and glaucoma suspects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Evoked Potential (VEP)</measure>
    <time_frame>1 examination, one hour</time_frame>
    <description>Diopsys Visual evoked potential (VEP) (Diopsys, Inc. Pine Brook, NJ) is used to objectively measure the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex. This is the strength of the signal recorded from the back of the head near where vision is processed in the brain while a visual stimulus is presented to patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal Nerve Fiber Layer Thickness</measure>
    <time_frame>1 examination, one hour</time_frame>
    <description>Optical coherence tomography (OCT) images provide measurement of the retinal nerve fiber layer thickness in microns.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Glaucoma Diagnosis</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma Suspects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <description>Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.</description>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_label>Glaucoma Suspects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <other_name>OCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Visual evoked potential</intervention_name>
    <description>Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.</description>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_label>Glaucoma Suspects</arm_group_label>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <other_name>VEP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1: Healthy Subjects

          -  intraocular pressure less than 22 millimeters of mercury (mmHg)

          -  normal appearing optic discs and retinal nerve fiber layer (RNFL)

          -  normal optical coherence tomography (OCT) RNFL thickness

          -  normal visual field (VF) results in both eyes.

        Group 2: Glaucoma Suspects

          -  glaucomatous appearance of optic discs and/or RNFL in at least one eye

          -  normal OCT

          -  normal VF results in both eyes.

        Group3: Glaucoma Patients

          -  Glaucomatous optic disc appearance (cup to disc ratio, rim thinning or RNFL defects)

          -  Repeatable intraocular pressure (IOP) of 23 mmHg or more, in at least one eye

          -  Repeatable abnormal VF tests

        Exclusion Criteria:

          -  inability to perform reliable VF or OCT

          -  visual acuity worse than 20/40

          -  refractive error greater than +/-5.00 diopters sphere, greater than +/- 3.00 diopers
             cylinder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L J Katz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Waisbourd M, Gensure RH, Aminlari A, Shah SB, Khanna N, Sood N, Molineaux J, Gonzalez A, Myers JS, Katz LJ. Short-duration transient visual evoked potentials and color reflectivity discretization analysis in glaucoma patients and suspects. Int J Ophthalmol. 2017 Feb 18;10(2):254-261. doi: 10.18240/ijo.2017.02.12. eCollection 2017.</citation>
    <PMID>28251085</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <results_first_submitted>December 18, 2017</results_first_submitted>
  <results_first_submitted_qc>October 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2018</results_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>L. Jay Katz MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Manuscript has been published.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Glaucoma patients, suspects and healthy subjects were recruited between 2011 and 2012 in the Glaucoma Service at Wills Eye Hospital, Philadelphia, Pennsylvania, USA.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Subjects</title>
          <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual fields in both eyes will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
        </group>
        <group group_id="P2">
          <title>Glaucoma Suspects</title>
          <description>45 Glaucoma suspects with glaucomatous optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology and normal visual field results will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
        </group>
        <group group_id="P3">
          <title>Glaucoma Patients</title>
          <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Subjects</title>
          <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual fields in both eyes for optical coherence tomography (OCT) and visual evoked potential testing (VEP).
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter wit</description>
        </group>
        <group group_id="B2">
          <title>Glaucoma Suspects</title>
          <description>45 Glaucoma suspects with glaucomatous optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology and normal visual field results will have optical coherence tomography and visual evoked potential.
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white check</description>
        </group>
        <group group_id="B3">
          <title>Glaucoma Patients</title>
          <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye will have optical coherence tomography and visual evoked potential.
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visu</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Evoked Potential (VEP)</title>
        <description>Diopsys Visual evoked potential (VEP) (Diopsys, Inc. Pine Brook, NJ) is used to objectively measure the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex. This is the strength of the signal recorded from the back of the head near where vision is processed in the brain while a visual stimulus is presented to patient.</description>
        <time_frame>1 examination, one hour</time_frame>
        <population>measurement is amplitude in microvolts (uV), the peak strength of the signal, when presented with low contrast stimuli</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subjects</title>
            <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual fields in both eyes will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma Suspects</title>
            <description>45 Glaucoma suspects with glaucomatous optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology and normal visual field results will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
          <group group_id="O3">
            <title>Glaucoma Patients</title>
            <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc (cup to disc ratio greater than 0.7, rim thinning or glaucomatous Retinal Nerve Fiber Layer defects) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Evoked Potential (VEP)</title>
          <description>Diopsys Visual evoked potential (VEP) (Diopsys, Inc. Pine Brook, NJ) is used to objectively measure the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex. This is the strength of the signal recorded from the back of the head near where vision is processed in the brain while a visual stimulus is presented to patient.</description>
          <population>measurement is amplitude in microvolts (uV), the peak strength of the signal, when presented with low contrast stimuli</population>
          <units>microvolts (uV) (amplitude)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="3.3"/>
                    <measurement group_id="O2" value="7.1" spread="3.9"/>
                    <measurement group_id="O3" value="4.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Retinal Nerve Fiber Layer Thickness</title>
        <description>Optical coherence tomography (OCT) images provide measurement of the retinal nerve fiber layer thickness in microns.</description>
        <time_frame>1 examination, one hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Healthy Subjects</title>
            <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual fields in both eyes will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma Suspects</title>
            <description>45 Glaucoma suspects with glaucomatous optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology and normal visual field results will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
          <group group_id="O3">
            <title>Glaucoma Patients</title>
            <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye will have optical coherence tomography (OCT) imaging and visual evoked potential (VEP) testing.
Optical coherence tomography (OCT), noninvasive imaging, provides micrometer-scale resolution. It utilizes Fourier domain (FD) techniques, with sensitivity advantage over traditional time domain (TD).
Visual evoked potential (VEP) objectively tests visual field by viewing a monitor at 1 meter of square black/white checks with electrodes on back of head where vision is processed.</description>
          </group>
        </group_list>
        <measure>
          <title>Retinal Nerve Fiber Layer Thickness</title>
          <description>Optical coherence tomography (OCT) images provide measurement of the retinal nerve fiber layer thickness in microns.</description>
          <units>microns (thickness)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" spread="8.7"/>
                    <measurement group_id="O2" value="87.5" spread="13.4"/>
                    <measurement group_id="O3" value="71.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 examination, one hour</time_frame>
      <desc>No adverse or serious adverse events were reported during this 1 examination, one hour study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Subjects</title>
          <description>42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual fields in both eyes for optical coherence tomography (OCT) and visual evoked potential testing (VEP).
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter wit</description>
        </group>
        <group group_id="E2">
          <title>Glaucoma Suspects</title>
          <description>45 Glaucoma suspects with glaucomatous optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology and normal visual field results will have optical coherence tomography and visual evoked potential.
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white check</description>
        </group>
        <group group_id="E3">
          <title>Glaucoma Patients</title>
          <description>49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye will have optical coherence tomography and visual evoked potential.
Optical Coherence Tomography: Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
Visual evoked potential: Visual evoked potential is a means of objectively testing visu</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. Participants were all recruited from one large urban setting. Age difference between the groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. L. Jay Katz</name_or_title>
      <organization>Wills Eye Hospital, Glaucoma Research Center</organization>
      <phone>215-928-3123</phone>
      <email>ljkatz@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

